Global sales of Xolair in 2020 reached $3.3 billion. AVT23 will be produced using BiosanaPharma’s proprietary 3C process technology, a fully continuous operation designed to allow for highly ...
Alvotech Holdings S.A. (“Alvotech”) announced that it has entered into an exclusive global licensing agreement with BiosanaPharma to co-develop AVT23 (also called BP001), a proposed biosimilar to ...
Alvotech (NASDAQ:ALVO) shares saw a positive lift Wednesday morning following the announcement that the biosimilar developer has significantly bolstered its production capabilities by acquiring Swiss ...
REYKJAVIK, Iceland & LEIDEN, Netherlands--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results